Adaptyx Biosciences Granted FDA Breakthrough Device Designation For Its Continuous Cortisol Monitoring Technology and Is Accepted into FDA’s Total Product Life Cycle Advisory Program

Adaptyx Biosciences received FDA Breakthrough Device Designation for its continuous cortisol monitoring technology and was accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP). The designations may accelerate regulatory engagement and development of the company’s cortisol-monitoring device, strengthening its clinical and commercialization pathway.